Phase 2 Trial Comparing Standard and Dose-Escalated Hypofractionated Radiation Therapy for Older Adults with Newly Diagnosed Glioblastoma

What this Trial Is About

Researchers are studying glioblastoma GBM, a fast-growing brain cancer affecting older adults who have special medical and care needs. This trial explores whether giving higher radiation doses in fewer sessions dose-escalated hypofractionation can improve treatment outcomes compared to the standard shorter radiation course. The study is a phase 2 randomized trial aiming to compare safety and effectiveness of these two radiation schedules in people aged 65 and older with newly diagnosed GBM. Participants will receive radiation therapy for three weeks, either as a standard hypofractionated regimen or a dose-escalated hypofractionated regimen with higher daily radiation doses. Both approaches deliver fewer radiation treatments than traditional schedules but differ in daily dose intensity. The study randomly assigns patients to one of these two groups to assess which approach may offer better results. During the trial, participants undergo screening to confirm eligibility, receive radiation treatments, and have follow-up visits to track symptoms and side effects. Researchers will measure overall survival, progression-free survival, treatment-related side effects, quality of life, mood, geriatric assessments, and performance status over up to six months after enrollment. The study will monitor participants for about one year on average to evaluate the effects of the treatments.

Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial